IBIO: חובות מצטברים של החברה iBio
iBio, Inc. utilizes the RubrYc AI engine for the precise identification of oncology targets, complementing this with eco-friendly protein synthesis in plants. The total amount of borrowed funds demonstrates the impact of these innovations on financial stability, where 0.00 is the current value of the indicator. The company is currently transforming its business, accelerating the development of immuno-oncology drugs through high-performance computing.
פילוחים אנליטיים ודוחות נתונים של חברת iBio (IBIO)
A conservative approach to analyzing iBio, Inc. (IBIO) requires assessing the debt load as the primary risk factor in the absence of operating profit. This indicator aggregates all external loans and credits; therefore, this debt trend chart allows for the determination of the AI-antibody development's dependence on borrowed capital and an assessment of the probability of insolvency prior to the platform's commercialization.